Literature DB >> 30151272

Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?

Veeravich Jaruvongvanich1, Tomoki Sempokuya1, Linda Wong2.   

Abstract

BACKGROUND: Many staging systems and liver reserve models have been proposed to predict hepatocellular carcinoma (HCC) prognosis. However, there is no consensus as to which model provides the best prognostic value. We aimed to investigate the prognostic role of 8 noninvasive models including the albumin-bilirubin index (ALBI), AST to platelet ratio index (APRI), Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP) system, Child-Pugh (CP) class, Fibrosis-4 (FIB-4) score, model for end-stage liver disease (MELD) score, and platelet-albumin-bilirubin index (PALBI) in patients with HCC.
METHODS: This is a retrospective study of 900 HCC patients. Patients who underwent transplantation were excluded. The Kaplan-Meier method was used to estimate the survival probabilities. Multivariate cox proportional hazard models were used to calculate the survival trend. P<0.05 was considered significant. The area under receiver operating characteristic curve (AUC) was calculated to test the discriminatory power over 1- and 3-year mortality and recurrence.
RESULTS: For predicting 1- and 3-year mortality, the CLIP score provided the highest AUC value, followed by the BCLC stage and the PALBI grade. For predicting 3-year recurrence, the CLIP score demonstrated the highest discriminative power followed by the PALBI grade, ALBI grade and BCLC system. However, all included models were found to be poor predictors for recurrence.
CONCLUSIONS: The CLIP score is more accurate prognostic model to predict mortality and recurrence than the BCLC stage. Regarding the liver reserve models, the PALBI is the most accurate prognostic models among 6 models to predict mortality and recurrence.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); liver reserve models; recurrence; staging systems; survival

Year:  2018        PMID: 30151272      PMCID: PMC6087858          DOI: 10.21037/jgo.2018.05.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems.

Authors:  C Cammà; V Di Marco; G Cabibbo; F Latteri; L Sandonato; P Parisi; M Enea; M Attanasio; M Galia; N Alessi; A Licata; M A Latteri; A Craxì
Journal:  Aliment Pharmacol Ther       Date:  2008-03-27       Impact factor: 8.171

2.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

Review 3.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

4.  Trends in the Mortality of Hepatocellular Carcinoma in the United States.

Authors:  Eliza W Beal; Dmitry Tumin; Ali Kabir; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Kenneth Washburn; Sylvester Black; Carl M Schmidt; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-08-07       Impact factor: 3.452

5.  Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto.

Authors:  I Levy; M Sherman
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 6.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

7.  Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.

Authors:  Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Mi Sung Park; Eun Hye Kim; Jinsil Seong; Do Youn Lee; Kwang-Hyub Han
Journal:  Liver Int       Date:  2012-04-23       Impact factor: 5.828

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups.

Authors:  Chih-Yun Lin; Kwong-Ming Kee; Jing-Houng Wang; Chuan-Mo Lee; Chao-Long Chen; Chi-Sin Changchien; Tsung-Hui Hu; Yu-Fan Cheng; Hsuan-Chih Hsu; Chih-Chi Wang; Tai-Yi Chen; Sheng-Nan Lu
Journal:  Liver Int       Date:  2008-03-05       Impact factor: 5.828

10.  Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation.

Authors:  Ji Yeon Seo; Won Kim; Jee Hye Kwon; Eun Hyo Jin; Su Jong Yu; Hwi Young Kim; Yong Jin Jung; Donghee Kim; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee
Journal:  Liver Int       Date:  2013-03-05       Impact factor: 5.828

View more
  9 in total

Review 1.  Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.

Authors:  Gauri Mishra; Ammar Majeed; Anouk Dev; Guy D Eslick; David J Pinato; Hirofumi Izumoto; Atsushi Hiraoka; Teh-Ia Huo; Po-Hong Liu; Philip J Johnson; Stuart K Roberts
Journal:  J Gastrointest Cancer       Date:  2022-05-30

2.  Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.

Authors:  Li Li; Xiaomi Li; Wendong Li; Jinglong Chen; Wei Li; Xiaoyan Ding; Yongchao Zhang
Journal:  BMC Cancer       Date:  2022-07-09       Impact factor: 4.638

3.  Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then.

Authors:  Takumi Kawaguchi; Shigeo Shimose; Sakura Yamamura; Dan Nakano; Masatoshi Tanaka; Takuji Torimura
Journal:  Ann Transl Med       Date:  2020-09

4.  Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis.

Authors:  Yi-Xin Xu; Yi-Bo Wang; Yu-Lin Tan; Cheng Xi; Xue-Zhong Xu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

5.  Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies.

Authors:  XinYue Zhang; Zhen Svn; MengSi Liv; MengNan Liu; YiHan Zhang; Qin Sun
Journal:  Front Med (Lausanne)       Date:  2021-11-26

6.  Prognostic Value of Platelet-Albumin-Bilirubin Grade in Child-Pugh A and B Patients With Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Rongqiang Liu; Rongqi Li; Min Zhang; Wenbin Liu; Hui Li; Dewei Li
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

7.  The comparison between albumin-bilirubin grade and Child-Pugh grade for assessing the prognosis of hepatocellular carcinoma after thermal ablation: a propensity score-matched analysis.

Authors:  Jiayi Zhang; Lin Zhao; Yan Zhou; Jianmin Ding; Qian Zhang; Xiang Jing
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

8.  Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery: A retrospective observational study.

Authors:  Binquan Wu; Xiaosi Hu; Hao Jin; Lei Zhou; Dengyong Zhang; Zhongran Man; Yong Wang; Song Yang; Qing Pang; Huichun Liu; Peiyuan Cui
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

9.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.